ARDS

FLCCC Alliance Announces Executive Leadership Expansion; Co-Founder Dr. Joseph Varon Appointed to the Board of Directors and Named President and Chief Medical Officer

Retrieved on: 
목요일, 5월 9, 2024
Pulmonology, Nursing care plan, Nephrology, Pneumonia, Central Jersey, Private practice, Research, Patient, Physician, Medicine, Hypertension, Trust, Vaccine, FLCCC, Asthma, Growth, Management

WASHINGTON, May 9, 2024 /PRNewswire/ -- The FLCCC Alliance announced today that Dr. Joseph Varon, one of the original co-founders of the organization, has been named president and chief medical officer; he has also been appointed to the board of directors. A globally recognized front line physician and highly published scientist, Dr. Varon is fluent in seven languages and is also the founder of multiple businesses, possessing outstanding organizational leadership skills that the FLCCC requires to execute the strategic plan formulated last fall to significantly expand its breadth of focus, reach, and global impact.

Key Points: 
  • WASHINGTON, May 9, 2024 /PRNewswire/ -- The FLCCC Alliance announced today that Dr. Joseph Varon, one of the original co-founders of the organization, has been named president and chief medical officer; he has also been appointed to the board of directors.
  • Three other founding FLCCC physicians/scientists have also stepped into expanded leadership roles pursuant to the strategic plan.
  • Dr. Pierre Kory is finalizing the transition of his responsibilities to Dr. Varon over the next 45 days.
  • We could not be where we are today without him," said Dr. Paul Marik, co-founder and chief scientific officer.

Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit

Retrieved on: 
월요일, 5월 6, 2024
Biotechnology, FDA, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, University, Pupa, Summit, COVID, UTHealth School of Dentistry, NIH, Abstract, Human services, UTMB, Development, TBI, Therapy, Patient, RIS, Diagnosis, White lung, American Thoracic Society

Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.

Key Points: 
  • Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.
  • This year, Chrysalis was selected as one of six “Critical Care Therapeutic Innovator” companies for oral presentation at the Summit.
  • “To be selected to present at the Respiratory Summit is a great honor for Chrysalis and confirms that experts in this field recognize the potential of TP508 (Chrysalin™) to prevent progression of acute lung injury,” said Dr. Darrell Carney, Chrysalis CEO.
  • Chrysalis BioTherapeutics is currently seeking investors and pharma partners for pulmonary and other indications including TBI, radiation therapy and mitigation chronic pulmonary diseases.

Vasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference

Retrieved on: 
월요일, 5월 6, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, TEK tyrosine kinase, ATS, Pneumonia, Safety, SARS-CoV-2, Pharmacokinetics, Conference, PEGylation, Acute respiratory distress syndrome, C40, Patient, National Research Council Canada, American Thoracic Society, Therapy, Risk, Infection, Pharmaceutical industry

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.

Key Points: 
  • Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.
  • Vasomune’s lead drug candidate AV-001, codeveloped with AnGes Inc, is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor.
  • Activation of the Tie2 receptor plays a critical role in promoting vascular stability, barrier integrity and endothelial quiescence.
  • “Vasomune is grateful to the National Research Council Canada for grant #IRAP-965762 which supported the Phase 1 study.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
화요일, 4월 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

Boston Medical Center Study Furthers Understanding of Lung Regeneration

Retrieved on: 
월요일, 4월 22, 2024
Mortality, Boston Medical Center, BMC, Cell Stem Cell, Cell, Chronic obstructive pulmonary disease, Boston University, Transplant, Regenerative medicine, Health, Bacteria, Respiratory disease, MD, Doctor of Philosophy, Disease, Respiratory system, Engineering, Acute respiratory distress syndrome, Pulmonary fibrosis, AT1, Science, Medicine, Knowledge, Infection, COPD, Vaccine

BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).
  • As science and medicine have progressed, researchers have identified a clear need for additional knowledge about lung cells to help improve patient health.
  • "Uncovering the ability to generate human alveolar epithelial type I cells (AT1s), and similar cell types, from pluripotent stem cells (iPSCs), has expanded our knowledge of biological processes and can significantly improve disease understanding and management," said Darrell Kotton, MD, Director, Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center.
  • This new study also furthers the CReM's goal of generating every human lung cell type from iPSCs as a pathway to improving disease management and provides a source of cells for future transplantation to regenerate damaged lung tissues in vivo.

Orphan designation: Plerixafor Treatment of acute respiratory distress syndrome (ARDS), 19/02/2024 Positive

Retrieved on: 
목요일, 4월 18, 2024
Patient, Committee, Acute respiratory distress syndrome, EMA, IRIS, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of acute respiratory distress syndrome on 19 February 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
목요일, 3월 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
월요일, 3월 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
화요일, 3월 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”

Global Ventilators Market Focused Insights and Outlook 2024-2029 - KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic & GE Healthcare Lead the Market - ResearchAndMarkets.com

Retrieved on: 
월요일, 3월 18, 2024
Managed Care, General Health, Oncology, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Surgery, Biotechnology, Nursing, Medical Supplies, Practice Management, Health, Growth, Prevalence, Application, Molecular Modeling Database, Incidence, Patient, Ventilation, Hospital, Acute respiratory distress syndrome, GE HealthCare, Asthma, Medtronic, COPD, Nursing care plan, ICU, USD, Ageing, Medical device

The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.

Key Points: 
  • The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.
  • The global ventilators market is one of the fastest-growing segments in the medical devices market.
  • The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth.
  • KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic plc, & GE Healthcare are some leading players currently dominating the global ventilators market.